Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Abstract
Kinase inhibitor resistance often involves upregulation of poorly understood “bypass” signaling pathways. Here, we show that extracellular proteomic adaptation is one path to bypass signaling and drug resistance. Proteolytic shedding of surface receptors, which can provide negative feedback on signaling activity, is blocked by kinase inhibitor treatment and enhances bypass signaling. In particular, MEK inhibition broadly decreases shedding of multiple receptor tyrosine kinases (RTK), including HER4, MET, and most prominently AXL, an ADAM10 and ADAM17 substrate, thus increasing surface RTK levels and mitogenic signaling. Progression-free survival of patients with melanoma treated with clinical BRAF/MEK inhibitors inversely correlates with RTK shedding reduction following treatment, as measured noninvasively in blood plasma. Disrupting protease inhibition by neutralizing TIMP1 improves MAPK inhibitor efficacy, and combined MAPK/AXL inhibition synergistically reduces tumor growth and metastasis in xenograft models. Altogether, extracellular proteomic rewiring through reduced RTK shedding represents a surprising mechanism for bypass signaling in cancer drug resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2016
- Source ID
- 10.1158/2159-8290.cd-15-0933
Entities
People
- Aaron S. Meyer
- Dennie T. Frederick
- Douglas A. Lauffenburger
- Frank B. Gertler
- Hakho Lee
- Hyungsoon Im
- Jenny Tadros
- Keith T. Flaherty
- Linda Griffith
- Madeleine J. Oudin
- Miles A Miller
- Ralph Weissleder
- Ryan J Sullivan
- Stephanie J. Wang
Organizations
- Harvard Medical School
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- National Institutes of Health
- United States Department of Defense